Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

August 31, 2015 3:16 PM ET


Company Overview of EpiVax, Inc.

Company Overview

EpiVax, Inc. is a biotechnology company that engages in the development and implementation of computational immunology tools. It provides interactive protein screening and reengineering interface for Web-based immunogenicity screening; and pre-deimmunization of a functional therapeutic report that is a concise description of a protein therapeutic candidate’s immunogenic potential. The company also offers EpiMatrix high throughput antibody immunogenicity prediction report that gives an overall assessment of potential clinical immunogenicity for a large set of antibody candidates; and Chinese hamster ovary protein predicted immunogenicity, an informatics tool to assess the immunogenic risk of ...

146 Clifford Street

Providence, RI 02903

United States

Founded in 1998





Key Executives for EpiVax, Inc.

Founder, Chief Executive Officer and Chief Scientific Officer
Chief Operating Officer and Chief Information Officer
Managing Director
Head of Marketing and Business Development
Director of Molecular Immunology
Compensation as of Fiscal Year 2015.

EpiVax, Inc. Key Developments

EpiVax, Inc. Presents at BIO-Europe Spring 2015, Mar-09-2015

EpiVax, Inc. Presents at BIO-Europe Spring 2015, Mar-09-2015 . Venue: Paris Expo - Porte de Versailles, Hall 5, Paris, France.

EpiVax, Inc. Presents at 7th annual Biotech Showcase Conference 2015, Jan-12-2015

EpiVax, Inc. Presents at 7th annual Biotech Showcase Conference 2015, Jan-12-2015 . Venue: Parc 55 Wyndham San, Francisco - Union Square, San Francisco, CA 94102, United States.

Biotest AG and EpiVax, Inc. Announce Collaborative Research Agreement

Biotest AG and EpiVax, Inc. announced a new collaborative research agreement. With this collaboration a novel, non-immunogenic Factor VIII (FVIII) should be developed. The coagulation factor VIII used for Hemophilia therapy will be altered in such a way that the immune system of the patients may not respond by developing inhibitory antibodies. The formation of inhibitory antibodies against the Coagulation factor VIII reduces its efficacy and may lead to severe bleeding disorders. Immunogenicity suppression will be also achieved through integration of EpiVax' proprietary Tregitope, an immune-modulating technology, with the FVIII treatment. A tolerized and de-immunized version of factor VIII would allow patients and their families to experience the benefits of FVIII treatment, which does not induce a reaction of the immune system (no immunogenicity) without the fear of developing inhibitory antibodies ('inhibitors') against the therapeutic factor VIII. Studies carried out by EpiVax and collaborators indicate that Tregitope may be useful for reducing the antibody formation (inducing tolerance) to transplants, protein drugs, and allergens by 'Tregitopes'.

Similar Private Companies By Industry

Company Name Region
Kineta Holdings II, LLC United States
PhycoBiologics, Inc. United States
Discgenics, Inc. United States
Radix Bio Solutions Ltd. United States
Scigenics, Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact EpiVax, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at